Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (“Jiuyuan Gene”) has released its 2025 annual report and issued a 171-page AGM circular outlining key financial results, a planned cash dividend, multiple corporate-governance revisions and other matters for shareholder approval on 15 June 2026 in Hangzhou. Financial highlights • Revenue in 2025 reached RMB1.31 billion. • Net profit attributable to shareholders totalled RMB0.14 billion. Dividend proposal • A final cash dividend of RMB0.57 (tax inclusive) for every 10 shares is proposed, equivalent to a total distribution of RMB13.77 million, representing c.9.95% of 2025 attributable net profit. • Dividend will be declared in RMB; H-share payments will be converted into Hong Kong dollars at the average RMB/HKD central parity rate for the five business days preceding the declaration date. Audit and financial reporting • Ernst & Young Hua Ming LLP and Ernst & Young are nominated for re-appointment as joint auditors for 2026, with fees capped at RMB2.62 million. • Shareholders will vote on the 2025 audited consolidated financial statements and the 2025 independent auditor’s report. Board and management changes • Nomination of Dr Huang Wenli as an independent non-executive director for the remainder of the first Board’s term. • Proposed directors’ remuneration for 2026: executive and non-executive directors to receive no director fees; independent non-executive directors to receive RMB0.18 million each. Corporate-governance overhaul • Proposal to abolish the Supervisory Committee, with its oversight duties to be assumed by the Board’s audit committee; related amendments to the Articles of Association and the rules of procedure for the Board and shareholders’ meetings are tabled. • General mandates sought to issue new H shares up to 20% of issued share capital and to repurchase up to 10% of outstanding H shares. Business scope expansion • Management requests shareholder approval to add “sales of additive manufacturing equipment” to the Company’s business scope. Annual General Meeting details • Date & time: 15 June 2026, 14:00 (PRC time). • Venue: Conference Room 3, No. 23, Eighth Street, Baiyang Street, Qiantang District, Hangzhou. • H-share register closure for AGM attendance: 10–15 June 2026 (both days inclusive); last registration date 9 June 2026. • Register closure for dividend entitlement: 22–24 June 2026; last share-transfer date 18 June 2026. If approved, the proposed amendments, dividend distribution and new mandates will take effect following the AGM.